Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Column

Clinical Pathways GPS
Adding Patient Navigation to the Clinical Pathway for Alzheimer Disease
04/11/2016
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Harold Freeman, MD
Ruth Gay
Mary Michael
David Digby
Patient navigation has proven capable of both improving health outcomes and decreasing costs to the health care system. Although the use of patient navigation in the context of cancer care has been described...
Patient navigation has proven capable of both improving health outcomes and decreasing costs to the health care system. Although the use of patient navigation in the context of cancer care has been described...
...
04/11/2016
Journal of Clinical Pathways

Advertisement

Pharma Insights
When Medication Price Deflates Perception of Therapeutic Effect
04/11/2016
Larry Blandford, PharmD—Column Editor
Stephen C Carter
Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...
Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...
...
04/11/2016
Journal of Clinical Pathways
Editor's Page
Value in Health Care: In the Eye of the Beholder
04/08/2016
Winston Wong, PharmD, Editor-in-Chief
Value is defined differently depending on who is defining it. Still, whether value is being defined by the health care provider, the payer, the patient, or industry, the importance of evidence-based treatment...
Value is defined differently depending on who is defining it. Still, whether value is being defined by the health care provider, the payer, the patient, or industry, the importance of evidence-based treatment...
Value...
04/08/2016
Journal of Clinical Pathways
Counterpoint
ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways
03/08/2016
Winston Wong, PharmD, Editor-in-Chief
The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...
The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...
The...
03/08/2016
Journal of Clinical Pathways

Advertisement

Viewpoint
Greater Alignment Among Oncology Clinical Pathways is Needed
03/08/2016
Edward Stepanski, PhD
A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...
A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...
A...
03/08/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Calling it Quits: Addressing Treatment Discontinuation on a Clinical Pathway
03/08/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Donald Ohloma, MS
Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...
Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...
...
03/08/2016
Journal of Clinical Pathways
Editor's Page
What`s in a Pathway?
03/08/2016
Winston Wong, PharmD, Editor-in-Chief
Whether or not a clinical pathways program will be effective is determined by the quality of the process used to develop the pathways. Which treatments go in the pathway; which stages of the care process are...
Whether or not a clinical pathways program will be effective is determined by the quality of the process used to develop the pathways. Which treatments go in the pathway; which stages of the care process are...
...
03/08/2016
Journal of Clinical Pathways

Advertisement

Clinical Pathways GPS
The Role of Patient Adherence in Successful Clinical Pathway Implementation
02/16/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
When considering the development of clinical pathways, the pathway itself is only the beginning; optimum outcomes cannot be realized unless patients follow their prescribed treatments. Simply having prescribers write...
When considering the development of clinical pathways, the pathway itself is only the beginning; optimum outcomes cannot be realized unless patients follow their prescribed treatments. Simply having prescribers write...
When...
02/16/2016
Journal of Clinical Pathways
Editor's Page
The Success of a Clinical Pathway Depends on Adherence
02/16/2016
Winston Wong, PharmD, Editor-in-Chief
Clinical pathways can be used to promote the standardization of evidence-based treatment strategies in order to ensure that every patient is receiving the best possible care. Yet, it is not enough to simply put...
Clinical pathways can be used to promote the standardization of evidence-based treatment strategies in order to ensure that every patient is receiving the best possible care. Yet, it is not enough to simply put...
...
02/16/2016
Journal of Clinical Pathways
Counterpoint
When Determining Value in Cancer Care, Don`t Forget the Patient
12/14/2015
Joan S. McClure, MS
Al B. Benson III, MD, FACP, FASCO
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...
Before...
12/14/2015
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use